FDA to Speed Biosimilar Approvals in Push to Cut Drug Costs

The FDA is planning to speed approvals of highly similar copies of expensive biologic drugs, the latest effort in President Donald Trump’s aggressive agenda to lower costs for medicines in the US.

Republicans Float Health-Care Fixes as Shutdown Impasse Drags On

Republicans are discussing policies for a health package focused on lowering insurance premiums and changing regulation of pharmacy middlemen as the shutdown standoff with Democrats continues.

Health Agency Pulls Obamacare Premium Spike in Fact Sheet Update

The Centers for Medicare & Medicaid Services deleted information on average premium spikes on HealthCare.gov from its annual open enrollment fact sheet, in a potential sign of how sensitive the issue is for the Trump administration ahead of next year’s midterm elections.

Anti-Tobacco Group Sees Industry Escalate Lobbying Under Trump

An anti-tobacco public health group report says the industry’s lobby has grown in 2025 compared with recent years, increasing efforts to delay or pull back federal and state measures that seek to reduce tobacco use.

Trump’s Pick for HHS Watchdog Deemed Dangerous by Top Democrat

President Donald Trump’s pick to serve as watchdog over the nation’s top health agency came under fire Wednesday during his nomination hearing over past efforts to rein in reproductive care and allegations of attacks on political opponents.

Latest Stories

Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle

Novo Nordisk A/S made an unsolicited bid for US biotech firm Metsera Inc., sparking a heated battle with Pfizer Inc. to get their hands on weight-loss treatments that both drugmakers want in order to regain lost ground in the booming market.

Merck Cuts Top End of Sales Guidance, Misses on Keytruda

Merck & Co. shaved the top end of its 2025 revenue guidance and failed to produce any standout sales beats for its medicines in the third quarter, adding to challenges the drugmaker is facing as it prepares for the loss of its star cancer drug Keytruda.

Beyond Abortion: The Fight Over Fetal Personhood Is Here

When do legal rights begin, at birth or before that? This video looks at the fetal personhood movement, and what it could mean for the future of abortion. We explore its history and the constitutional argument underpinning it.

From Across Bloomberg Law

Business & PracticeEnvironment & EnergyEnvironmental, Social & Governance (ESG)The United States Law Week
  • Business & Practice
  • Environment & Energy
  • Environmental, Social & Governance (ESG)
  • The United States Law Week

Covid Vaccine & Personal Data: Does HIPAA Still Matter?

EXPLORE BLOOMBERG LAW

Get the latest legal, regulatory, and enforcement news and analysis, as well as in-depth business and industry covering in the following areas: